Rivaroxaban Prescription

Initial Triple Antithrombotic Therapy

According to the general principles of antithrombotic therapy, patients who have not previously received anticoagulant drugs are indicated to start treatment with the so-called triple regimen. This approach has the highest level of recommendation consensus (ESC IA, LOR A, LOE 1).

At the initial stage, antiplatelet monotherapy, anticoagulant monotherapy, or dual therapy is strictly not used. The physician is required to prescribe a combination of three active components:

1. Acetylsalicylic acid (ASA).
2. Platelet P2Y12 receptor inhibitor (noting importantly that the pharmacological target is specifically the P2Y12 receptor).
3. Parenteral anticoagulant (administered by injection).

Only after completing the initial phase of therapy is further strategy considered, involving the discontinuation of parenteral administration and a transition to oral formulations.

Transition to Oral Agents and Indications

The subsequent transition from a parenteral anticoagulant requires the selection of a reliable oral agent. Clinical guidelines suggest using rivaroxaban, apixaban, dabigatran etexilate, edoxaban, or indirect anticoagulants (vitamin K antagonists) as options.

The further treatment regimen may include either a combination of ASA and a P2Y12 inhibitor or, in the presence of strict indications, a combination of an oral anticoagulant and an antiplatelet agent.

Long-term administration of anticoagulants (including rivaroxaban) is strictly regulated. The main indications for their prolonged prescription are the following clinical conditions:

• Presence of atrial fibrillation or atrial flutter (AF/AFL);
• Established mechanical heart valve prosthesis;
• Diagnosed left ventricular (LV) mural thrombosis;
• Deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

Rules for Extending Therapy Beyond 12 Months

In certain cases, patients require the extension of dual antithrombotic therapy for a period exceeding 12 months. This strategy has a high level of evidence (ESC IIaA, LOR B, LOE 2).

Prolongation of treatment is possible exclusively upon the simultaneous fulfillment of three critical conditions:

• The patient maintains a persistently high risk of coronary events.
• The risk of bleeding is assessed by the attending physician as low.
• During the first twelve months of treatment, the patient had completely no episodes of bleeding.

If all conditions are met, the physician may choose one of two extended therapy regimens. The first is a combination of ASA and a P2Y12 receptor inhibitor. The second regimen includes ASA and rivaroxaban. When choosing the second regimen, rivaroxaban is prescribed in a strictly defined dosage: 2.5 mg twice daily.

The primary goal of such long-term treatment is to maximize the reduction of the cumulative risk of ischemic events, prevent mortality, and protect against recurrent myocardial infarction. It is extremely important to remember that throughout the entire period of extended therapy, the ratio of expected benefit to the potential risk of hemorrhagic complications for the patient must be regularly re-evaluated.

Class and exam questions

What else to study on this topic

• Adjustment of anticoagulant dosages in renal impairment (according to Appendix A3 of clinical guidelines).
• Comparative characteristics of oral anticoagulants: rivaroxaban, apixaban, dabigatran, and edoxaban.
• Mechanism of action of platelet P2Y12 receptor inhibitors as part of triple therapy.
• Scales and criteria for assessing bleeding risk during long-term antithrombotic therapy.
• Specifics of using vitamin K antagonists during the transition phase from parenteral drugs.

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.